Steroidal Triglycosides from Hippasteria kurilensis
Journal of Natural Products, 2008, Vol. 71, No. 5 797
Chart 1
1
column (2.5 × 15 cm) using CHCl3/EtOH (stepwise gradient, 4:1 f
1:2). HPLC separation of collected subfractions, containing nonsulfated
steroids, on a Diasfer-110-C18 column (10 µm, 250 × 15 mm, 2.5
mL/min) with 65% EtOH as the eluent system, followed by purification
on a Kromasil 100A-C18 column (5 µm, 250 × 4.6 mm, 0.5 mL/min)
with 80% MeOH as the eluent system, yielded pure 2 (1.4 mg, Rf 0.65),
3 (2.2 mg, Rf 0.65), 4 (1.7 mg, Rf 0.75), and 7 (1.0 mg, Rf 0.85). HPLC
separation of collected subfractions, containing sulfated steroids, on a
Diasfer-110-C18 column (10 µm, 250 × 15 mm, 2.5 mL/min) with
55% EtOH as the eluent system gave pure 1 (3.7 mg, Rf 0.55), 5 (1.0
mg, Rf 0.78), and 6 (1.1 mg, Rf 0.78).
Compound 6: amorphous powder; [R]25 (0 (c 0.1, MeOH); H
D
NMR data, see Table 2; 13C NMR data, see Table 3; LSIMS(+) m/z
607 [M + Na]+, 505 [(M + Na) - 102]+; 487 [(M + Na) - 120]+,
454 [(M + Na) - 153]+; LSIMS(-) m/z 561 [M - Na]-, 408 [(M -
Na) -153]-, 97 [HSO4]-, 80 [SO3]-; HR MALDI-TOFMS (+) m/z
607.2587 [M + Na]+ (calcd for C27H45O10SNa2, 607.2529).
Compound 7: amorphous powder; [R]25 +14.7 (c 0.1, MeOH);
D
1H NMR data, see Table 2; 13C NMR data, see Table 3; EIMS m/z (%)
468 [M]+ (3), 450 [M - H2O]+ (75), 432 [M - 2H2O]+ (100), 414 [M
- 3H2O]+ (75), 396 [M - 4H2O]+ (30), 378 [M - 5H2O]+ (8), 321
(78); HR MALDI-TOFMS (+) m/z 491.3369 [M + Na]+ (calcd for
C27H48O6Na, 491.3349).
Kurilensoside A (1): amorphous powder; [R]25D -48.0 (c 0.1; H2O/
1
MeOH, 3:1); H NMR data, see Table 1; 13C NMR data, see Table 3;
Acid Hydrolysis of 1. A solution of glycoside 1 (1 mg) in aqueous
2 M CF3COOH (1 mL) was heated at 100 °C for 2 h in a sealed
ampule. The reaction mixture was evaporated in vacuo, and the
residue was dissolved in H2O and extracted with CHCl3 twice. The
monosaccharides 2-O-methylxylose and arabinose were identified
in the aqueous layer by TLC on Si gel in BuOH/EtOH/H2O (4:1:2).
The aqueous layer was evaporated to dryness. Then, pyridine (0.5
mL) and NH2OH · HCl (2 mg) were added to the dried residue, and
the mixture was heated at 90 °C for 40 min. After that time, 0.5
mL of Ac2O was added and the heating at 90 °C was continued for
a further 1 h. The solution was concentrated, and the resulting
aldononitrile peracetates were analyzed by GLC using standard
aldononitrile peracetates as reference samples.
MALDI-TOFMS (+) m/z 1003 [M + Na]+, 901 [(M + Na) - 102]+,
871 [(M + Na) - 132]+, 857 [(M + Na) - 146]+, 769 [(M + Na) -
102 - 132]+, 637 [(M + Na) - 102 - 2 × 132]+, 619 [637 - H2O]+,
601 [637 - 2 × H2O]+; MALDI-TOFMS (-) m/z 957 [M - Na]-,
825 [(M - Na) - 132]-, 811 [(M - Na) - 146]-, 679 [(M - Na) -
132 - 146]-; HR MALDI-TOFMS (+) m/z 1003.4223 [M + Na]+
(calcd for C43H73O21SNa2, 1003.4160).
Kurilensoside B (2): amorphous powder; [R]25D -16.8 (c 0.1; H2O/
1
MeOH, 3:1); H NMR data, see Table 1; 13C NMR data, see Table 3;
LSIMS(+) m/z 931 [M + Na]+, 753 [(M + Na) - 178]+, 621 [(M +
Na) - 178 - 132]+; LSIMS(-) m/z 907 [M - H]-, 729 [(M - H)
-178]-; HR MALDI-TOFMS (+) m/z 931.4821 [M + Na]+ (calcd
for C44H76O19Na, 931.4879).
Partial Acid Hydrolysis of 1. A solution of 1 (2 mg) in 50%
aqueous CH3COOH (1 mL) was stirred at 54 °C for 48 h. The
reaction mixture was evaporated in vacuo, and the residue was
subjected to HPLC separation on a Diasfer-110-C18 column (5 µm,
250 × 4 mm, 0.5 mL/min) with 65% EtOH as the eluent system to
Kurilensoside C (3): amorphous powder; [R]25D -23.2 (c 0.1; H2O/
1
MeOH, 3:1); H NMR data, see Table 1; 13C NMR data, see Table 3;
LSIMS(+) m/z 931 [M + Na]+; LSIMS(-) m/z 907 [M - H]-, 743
[(M - H) - 164]-; HR MALDI-TOFMS (+) m/z 931.4934 [M +
Na]+ (calcd for C44H76O19Na, 931.4879).
1
give 1a (0.5 mg). H NMR data of 1a were identical with those of
Kurilensoside D (4): amorphous powder; [R]25D -4.6 (c 0.1; H2O/
linckoside L1.3
1
MeOH, 1:6); H NMR data, see Table 2; 13C NMR data, see Table 3;
Preparation of (R)-MTPA Ester of Compound 1a. Compound 1a
(0.5 mg) was treated with S-(+)-R-methoxy-R-(trifluoromethyl)phe-
nylacetyl (MTPA) chloride (3 µL) in dry pyridine (100 µL) for 4 h at
room temperature. After removal the solvent, the product was purified
on a Si gel column (0.8 × 9 cm) using hexane/CHCl3 (1:4) to obtain
LSIMS(+) m/z 769 [M + Na]+; LSIMS(-) m/z 745 [M - H]-, 599
[(M - H) -146]-; HR MALDI-TOFMS (+) m/z 769.4394 [M + Na]+
(calcd for C38H66O14Na, 769.4351).
Compound 5: amorphous powder; [R]25D +8.1 (c 0.1, MeOH); 1H
NMR (CD3OD, 500 MHz) δ 0.89 (3H, d, J ) 6.7 Hz, H3-27), 0.91
(3H, d, J ) 6.7 Hz, H3-26), 0.94 (3H, d, J ) 6.6 Hz, H3-21), 1.23 (3H,
s, H3-19), 1.26 (3H, s, H3-18), 1.41 (1H, d, J ) 5.8 Hz, H-14), 1.72
(1H, dd, J ) 2.3, 12.2 Hz, H-5), 2.35 (1H, m, H-16), 3.20 (1H, m,
H-24), 3.48 (1H, m, H-3), 4.21 (1H, br s, H-4), 4.24 (1H, d, J ) 2.7
Hz, H-7), 4.50 (1H, ddd, J ) 2.1, 5.5, 7.6 Hz, H-15), 5.03 (1H, dd, J
) 2.7, 12.1 Hz, H-6); 13C NMR data were identical with those reported
by Levina et al.;9 MALDI-TOFMS (+) m/z 609 [M + Na]+, 507 [(M
+ Na) - 102]+, 489 [(M + Na) - 120]+.
1
the corresponding (R)-MTPA ester of 1a (0.3 mg): selected H NMR
(CD3OD, 500 MHz) δ 0.80 (3H, d, J ) 6.7 Hz, H3-27), 0.82 (3H, d,
J ) 6.7 Hz, H3-26), 0.92 (3H, d, J ) 6.2 Hz, H3-21), 0.98 (3H, s,
H3-18), 1.37 (3H, s, H3-19).
Solvolysis of 5. A solution of 5 (1.0 mg) in a mixture of pyridine
(0.5 mL) and dioxane (0.5 mL) was heated at 120 °C for 5 h. The
reaction mixture was evaporated to dryness and purified on a Florisil
column (0.8 × 2 cm) using CHCl3/EtOH (3:1) to obtain the desulfated
1
derivative 5a (0.5 mg): H NMR (CD3OD, 500 MHz) δ 0.88 (3H, d,